opriate. Then, the Calcijex dose should be reinitiated at a lower dose. Doses may need to be reduced as the PTH levels decrease in response to the therapy. Thus, incremental dosing must be individualized and commensurate with PTH, serum calcium and phosphorus levels. The following is a suggested approach in dose titration:
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Discard unused portion.
PTH Levels Calcijex Dose
the same or increasing increase
decreasing by < 30% increase
decreasing by > 30%, < 60% maintain
decreasing by > 60% decrease
one and one-half to three times
the upper limit of normal maintain
Calcijex (calcitriol injection) is supplied as follows:
Mfd. by:
Hospira, Inc.
Lake Forest, IL 60045 USA
For:
Abbott Laboratories
North Chicago, IL 60064 USA
©Abbott 2004
Printed in USA
List Container Concentration Fill
8110 Ampul 1 mcg/mL 1 mL
NDC 0074-8110-31
1 mL Single-dose 5 Ampuls
CALCIJEX® Calcitriol Injection (1 mcg/mL)
For I.V. use. Protect from light. Keep ampuls in package until time of use.
Each mL contains calcitriol, 1 mcg; polysorbate 20, 4 mg; sodium ascorbate 2.5 mg added. May contain hydrochloric acid and/or sodium hydroxide for pH adjustment. pH is 6.5 (5.9 to 7.0). Contains no more than 1 mcg/mL of aluminum. Usual dosage: See insert. Store at controlled room temperature 15° to 30°C (59° to 86°F).
©Abbott 2004
Mfd. by: Hospira, Inc., Lake Forest, IL 60045 USA For: Abbott Laboratories, North Chicago, IL 60064 USA
Rx only
Manufacturer
Abbott Laboratories
Active Ingredients
Source
U.S. National Library of Medicine
DailyMed
Last Updated: 2nd of March 2011
